Together with the UCLA Technology Development Group, Dr. Genieser obtained patent protection and manages the international patent portfolio for the Xtandi® therapeutic, developed in the groups of Profs. Michael Jung and Charles Sawyers, for the treatment of castration-resistant prostate cancer. Dr. Genieser holds a Ph.D. from the Massachusetts Institute of Technology and a B.S.E. from Princeton University. He applies his research experience in academic and industrial settings to anticipate challenges faced by and counsel his technology-driven clients, and Dr. Genieser develops and carries out integrated strategies for protecting and commercializing his clients’ inventions.